Recent Advances in Immunotherapy for Acute Myeloid Leukemia --Review.
10.19746/j.cnki.issn1009-2137.2019.02.053
- Author:
Bin XU
1
;
Yi XIAO
2
Author Information
1. Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.
2. Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China E-mail: yixiao@tjh.tjmu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Cancer Vaccines;
Humans;
Immunotherapy;
Immunotherapy, Adoptive;
Leukemia, Myeloid, Acute;
therapy;
T-Lymphocytes
- From:
Journal of Experimental Hematology
2019;27(2):633-636
- CountryChina
- Language:Chinese
-
Abstract:
Currently, the traditional chemotherapeutic drugs for acute myeloid leukemia (AML) showed significant curative efficacy, including the improving long-term prognosis and the life quality of the patients, however the traditional chemotherapeuatic drugs showed the some limitatious in the aspects of enhancing the complete remission rate of newly diagnosed AML patients, overcoming the relapse after remission,as well as the primary and secondary drug-resstance to chemotherapeutics. In order to improve the long-term prognisis of patients, the immuno therapy will the best choice for these patients. This review sammarizes the main current advance of immunotherapy of AML at home and abroad, such as antibody-drug conjugate(ADC), bispecific T cell engager (BiTE), chimeric type of antigen receptor T cell (CAR-T) therapy, checkpoint inhibitors; dendritic cell vaccination and peptide vaccines; natural killer cell (NK) therapy and so on.
